Intestinal anti-inflammatory effects of oligosaccharides derived from lactulose in the trinitrobenzenesulfonic acid model of rat colitis.
Intestinal microbiota modulation is becoming an interesting approach to manage inflammatory bowel disease and can be achieved by the administration of prebiotics. Previous studies showed the intestinal anti-inflammatory effects of the prebiotic lactulose. The aim of the present study was to test the preventative effects of oligosaccharides derived from lactulose with prebiotic properties (OsLu) in the trinitrobenzenesulfonic acid model of rat colitis and compare them with those of lactulose. Both treatments modified bacterial profile in intestinal contents, increasing the bifidobacteria and lactobacilli counts and up-regulating the production of short-chain fatty acids, although OsLu generated a larger amount. OsLu also inhibited to a greater extent different pro-inflammatory markers such as interleukins (IL) 1, 6, 12, and 23 and chemokines (MCP-1 and CINC-1). However, both prebiotics equally restored colonic epithelial integrity, evaluated both with a histological score (OsLu, 9.8 ± 2.2; and lactulose, 12.1 ± 2.1, vs colitic control, 27.3 ± 3.3) and by measuring several key proteins of the mucosal barrier (MUC-2, MUC-3, and TTF-3). OsLu effect was also associated with an inhibition of iNOS expression and a reduction of Th17 cell activity in the inflamed tissue that facilitated the intestinal mucosa barrier recovery. In conclusion, OsLu showed a better anti-inflammatory profile than lactulose in this model of experimental colitis.
CIBER-EHD, Department of Pharmacology, ibs.GRANADA, Center for Biomedical Research (CIBM), University of Granada , Granada, Spain.
Francesca
F
Algieri
Alba
A
Rodríguez-Nogales
Natividad
N
Garrido-Mesa
Teresa
T
Vezza
José
J
Garrido-Mesa
M Pilar
MP
Utrilla
Antonia
A
Montilla
Alejandra
A
Cardelle-Cobas
Agustín
A
Olano
Nieves
N
Corzo
Eduardo
E
Guerra-Hernández
Antonio
A
Zarzuelo
M Elena
ME
Rodriguez-Cabezas
Julio
J
Galvez
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000737:chemistry; D018925:Chemokines / Q000235:genetics / Q000276:immunology; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007378:Interleukins / Q000235:genetics / Q000276:immunology; D007422:Intestines / Q000382:microbiology; D007792:Lactulose / Q000008:administration & dosage* / Q000737:chemistry; D064307:Microbiota / Q000187:drug effects; D009844:Oligosaccharides / Q000008:administration & dosage* / Q000737:chemistry; D056692:Prebiotics / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D014302:Trinitrobenzenesulfonic Acid / Q000009:adverse effects
D000893:Anti-Inflammatory Agents; D018925:Chemokines; D007378:Interleukins; D009844:Oligosaccharides; D056692:Prebiotics; D007792:Lactulose; D014302:Trinitrobenzenesulfonic Acid